Clinical Research Directory

Inclusion Criteria: * Patients between 16 and 60 years-old with refractory or relapsed ALL (≥1% of anomalous blasts by flow cytometry in bone marrow or peripheral blood) after one or two lines of therapy, regardless of their phenotype or baseline genetic alteration; * Patients are eligible after allogeneic HSCT as long as patients are not actively being treated for graft-versus-host-disease (GvHD). Exclusion Criteria: * Burkitt leukemia; * Prior myeloproliferative disease; * Drug allergies; * Eastern Cooperative Oncology Group (ECOG) scale \>2; * Total bilirubin\>2x upper limit of normal (ULN); * Transaminases\>5x ULN; * Creatinine\>2,5 mg/dl; * Active uncontrolled infection; * History of asparaginase-induced pancreatitis; * Prior exposure to bortezomib; * Heart failure New York Heart Association (NYHA) Class III or IV; * Patients with more than 400mg/m2 lifetime exposure of anthracycline; * Severe psychiatric disorder which prevents adequate compliance; * Refusal to participate in the study.